The stock of Design Therapeutics Inc. (NASDAQ:DSGN) increased by $0.03 on Friday to finish at $2.08, up 1.46 percent. The last five days have seen an average of 1,204,120 shares of common stock traded. 1 time new highs were reached in the current year, with a fall of -$8.18. The average number of shares traded over the last 20 days was 1,610,895, while the average volume over the last 50 days totaled 804,760.
DSGN stock dropped -70.54% since last month. On 08/22/23, the company’s shares reached a one-month low of $1.94. The stock touched a high of $25.03 on 01/03/23, after rallying from a low of $1.94 in 52 weeks. The price of DSGN stock has declined by -79.73% or -$8.18 this year, reaching a new high 1 time. Still, the stock price is down -91.69% from the 52-week high.
Insider Transactions
DSGN stock investors should be aware that Design Therapeutics Inc. (DSGN) stock had its last reported insider trading activity 251 days ago on Dec 20. On Dec 20, 10% Owner SR One Capital Fund I Aggregat acquired 40,000 shares at $8.14 each. This transaction resulted in the insider spending $325,432. On Dec 20, George Simeon added 40,000 shares at a price of US$8.14. After the transaction, the insider now owns 6,526,476 shares. President and CEO Siffert Joao MD had earlier bought 6,300 shares on Dec 20 for $8.38 a share. The transaction was completed for $52,762.
Financial Health
For the three months ended June 29, Design Therapeutics Inc.’s quick ratio was 25.20, while its current ratio was 25.20, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $67.59 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. DSGN’s return on assets (ROA) during the last 12 months has been -22.30%. In the meantime, the return on equity (ROE) for the last 12 months was -23.20%.
Earnings Surprise
According to Design Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29. It was predicted that Design Therapeutics Inc.’s quarterly earnings would be -$0.36, but it ended up being -$0.4. At the end of Design Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 14.84 million, while its total debt was $3.38 million. Equity owned by shareholders amounts to $55.99 million.
Technical Picture
Here’s a quick look at Design Therapeutics Inc.’s (DSGN) price momentum from a technical perspective. As of 25 August, the RSI 9-day stood at 13.11%, suggesting the stock is oversold, with a 595.35% historical volatility rate.
The stochastic %K and %D were 2.18% and 2.11% respectively, while the average true range (ATR) was 0.45. Based on the 14-day stochastic reading of 2.38%, the RSI (14) reading is 18.31%. On the 9-day MACD Oscillator, the stock is at -0.03, and the 14-day reading is at -1.93.
Analyst Ratings
Design Therapeutics Inc. (NASDAQ: DSGN) was downgraded by Wedbush to a a Neutral rating in its latest research report. The stock was previously rated as a an Outperform. Analysts have assigned Design Therapeutics Inc. (DSGN) an Hold rating. DSGN is a stock that is recommended for selling by 0 brokerage firms, while 3 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 1 other recommend it as a buy.
What is DSGN’s price target for the next 12 months?
The current consensus forecast for the stock is between $6.00 and $42.00, with a median target price of $6.50. In analyzing these forecasts, the average price target given by analysts for Design Therapeutics Inc. (DSGN) is $15.25.
